Allen, changing the name doesn't change the facts.
EUOT gets 7% of the gross sales of Nucap. GBMR had to get permission from EUOT to sublicense the product to NNRF.
GBMR was diluted by 1000% in the last year.
The o/s is now over 200,000,000 with 900,000,000 authorized.
The annual revenuse are ~$50,000 and the expenses are over $1,000,000.
I'm sure they'll last until the next reverse split.